Abstract
ObjectivesTo evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs.MethodsIn this...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have